Oxolanes
Apexbio Technology LLC Oligomycin Complex 1404-19-9 10mg
Oligomycin Complex is a mixture composed primarily of Oligomycin A B and C It functions as a mitochondrial ATP synthase inhibitor targeting specifically the F0 subunit to disrupt oxidative phosphorylation via inhibition of ATP generation Oligomycin A exhibits selective inhibition of ATP synthase with reported GI50 at approximately 270 nM By blocking mitochondrial ATP synthesis oligomycin promotes cellular metabolic shift from oxidative phosphorylation to glycolysis In cell culture studies using various cancer cell lines oligomycin treatment has been demonstrated to suppress mitochondrial respiration and can induce apoptosis Additionally oligomycin has been employed in research to examine cellular bioenergetics adaptations mitochondrial-related apoptosis pathways and synergy of chemotherapeutic combinations in vitro
Medchemexpress LLC Rk-582 | 2171388-28-4 | 98.05% | 510.60 | 25 MG
RK-582 is a tankyrase inhibitor and an orally bioavailable growth inhibitor, acting as an antitumor agent. It is suitable for research on colorectal cancer. This compound potently inhibits human tankyrase-1 and tankyrase-2 catalytic activity with high selectivity over PARP1, PARP2, and PARP10. It also inhibits Wnt/β-catenin signaling and the growth of COLO-320DM human colorectal cancer cells.
- Inhibits tankyrase-1 and tankyrase-2 catalytic activity
- Demonstrates high selectivity over PARP1, PARP2, and PARP10
- Inhibits Wnt/β-catenin signaling
- Potently inhibits the growth of COLO-320DM human colorectal cancer cells
- Modulates Wnt/β-catenin signaling by stabilizing AXIN2 and reducing active β-catenin
Medchemexpress LLC Moenomycin complex | 11015-37-5 | MFCD01742468 | 99.9% | 1583.6 g/mol | C69H107N4O35P | 5 MG
Moenomycin complex is a mixture of moenomycin antibiotics that potently inhibit bacterial transglycosylase enzymes, blocking the transglycosylase activity of class A penicillin-binding proteins (PBPs) and disrupting peptidoglycan biosynthesis. Supplied as a powder for research use, it is used in studies of bacterial cell wall synthesis, antibiotic mechanism of action, and in vitro antibacterial assays.
- Potent transglycosylase inhibitor for mechanistic studies.
- Inhibits class A penicillin-binding proteins, blocking cell wall biosynthesis.
- High purity suitable for in vitro assays.
- Supplied as a powder for convenient storage and handling.
- Available in small pack sizes for scale-appropriate experiments.
- Useful in antibacterial activity assays and biochemical characterization.
Medchemexpress LLC RK-582 | 2171388-28-4 | 98.05% | 510.60 | 50 MG
RK-582 is a tankyrase inhibitor, antitumor agent, and orally bioavailable growth inhibitor. It has an IC50 of 36.1 nM against human tankyrase-1 and 39.2 nM against human tankyrase-2. In APC-mutated colorectal cancer cells, sensitivity to RK-582 correlates with the level of active β-catenin, while drug resistance is associated with PIK3CA mutation. RK-582 can be used for the research of colorectal cancer.
- Tankyrase inhibitor
- Antitumor agent
- Orally bioavailable growth inhibitor
- IC50 of 36.1 nM against human tankyrase-1
- IC50 of 39.2 nM against human tankyrase-2
- Correlates with active β-catenin levels in APC-mutated colorectal cancer cells
- Useful for colorectal cancer research
Medchemexpress LLC KTX-582 | 2573298-13-0 | 98.7% | 872.93 | 5 MG
KTX-582 is a potent IRAK4 degrader that can induce apoptosis in MYD88MT DLBCL and is efficient in inducing in vivo tumor regressions in a lymphoma model. It degrades IRAK4 in whole blood monocytes and lymphocytes with high potency.
- Potent IRAK4 degrader with DC50 values of 4 nM for IRAK4 and 5 nM for Ikaros
- Induces apoptosis in MYD88MT DLBCL
- Efficient in inducing in vivo tumor regressions in a lymphoma model
- Degrades IRAK4 in whole blood monocytes and lymphocytes with IC50s of less than 0.05 μM
- Inhibits IRAK4 in human whole blood LPS TNFα with an IC50 of 0.05 to 1 μM
- Exhibits antiproliferative activity against human OCI-Ly10 cells (IC50: 14 nM)
Sigma Aldrich Fine Chemicals Biosciences VHL Protein Complex Active
The VHL complex is a multi-subunit ubiquitin ligase composed of VHL, Elongin B, Elongin C, Cul2 and Rbx1. The VHL protein serves as the substrate recognition component and is linked by Elongin C to a heterodimeric Cul2/Rbx1 module that functions as a potent activator of the ubiquitination of target proteins by an E2 conjugating enzyme. Elongin B interacts with the complex through Elongin C and appears to stabilize the binding of Elongin C to VHL. The primary function of the VHL complex is to regulate HIF (hypoxia inducible factor) activity by targeting the hydroxylated HIF-1alpha subunit for ubiquitination and rapid proteasomal degradation under normoxic conditions. It therefore plays an important role in the regulation of hypoxia-inducible genes such as the vascular endothelial growth factor (VEGF) and glucose transport-1 (Glut-1). Mutations in VHL are associated with the inherited von Hippel-Lindau (VHL) cancer syndrome and numerous forms of renal cell carcinoma.
